Effect of Nicotine on Chronic Pelvic Pain
Primary Purpose
Pelvic Pain
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Placebo
Nicotine (5 mg)
Nicotine (10 mg)
Sponsored by
About this trial
This is an interventional treatment trial for Pelvic Pain focused on measuring chronic pain, pelvic pain, nicotine patch
Eligibility Criteria
Inclusion Criteria:
- Chronic pelvic pain
- Aged 18-60 years
- Female
Exclusion Criteria:
- Uncontrolled hypertension
- Cardiovascular disease
- Current analgesic abuse
- Pregnancy
- Current usage of nicotine patch or gum
- Allergy to adhesive tape
Sites / Locations
- Columbia University Medical Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Placebo Comparator
Experimental
Experimental
Arm Label
Placebo
Nicotine (5 mg)
Nicotine (10 mg)
Arm Description
Subjects applied a placebo patch (0 mg) in the morning and removed it at bedtime for one day.
Subjects applied a nicotine patch (5 mg) in the morning and removed it at bedtime for one day.
Subjects applied a nicotine patch (10 mg) in the morning and removed it at bedtime for one day.
Outcomes
Primary Outcome Measures
Pain Score
Pain assessment by patient reported in visual analog score (VAS) with 0=no pain and 10=worst pain.
Secondary Outcome Measures
Patient Self-assessment of Psychological Distress
Patient self-assessment of psychological distress in brief rating scale with no psychological distress=0 and maximum psychological distress=90.
Number of Participants Who Reported an Increase in Daily Pain Medication Regime
Number of participants who reported increases in daily pain medication after treatment with each intervention compared to their normal daily pain medication regime.
Nausea
Nausea assessment by patient reported on a numerical rating scale (NRS) with 0=no nausea and 10=extreme nausea.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00440505
Brief Title
Effect of Nicotine on Chronic Pelvic Pain
Official Title
Effect of Nicotine on Chronic Pelvic Pain
Study Type
Interventional
2. Study Status
Record Verification Date
July 2018
Overall Recruitment Status
Completed
Study Start Date
February 2004 (undefined)
Primary Completion Date
June 2008 (Actual)
Study Completion Date
June 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Columbia University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to test whether transdermal nicotine reduces pain among women with chronic pelvic pain.
Detailed Description
Potential subjects are female non-smokers presenting to their physicians for treatment of chronic pelvic pain. When consented, the subjects fill out a questionnaire on demographic information and pain experience. The trial is conducted at home over three days. Each subject uses three different levels of nicotine (0mg, 5mg, and 10mg) administered in a random order; the study is double-blinded and patients act as their own controls. Subjects apply the placebo or nicotine patches in the morning and remove them in the evening when they fill out a pain diary for the day. During the study, patients will continue their typical course of pain medication and report pain medication use in the pain diary.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pelvic Pain
Keywords
chronic pain, pelvic pain, nicotine patch
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
20 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Subjects applied a placebo patch (0 mg) in the morning and removed it at bedtime for one day.
Arm Title
Nicotine (5 mg)
Arm Type
Experimental
Arm Description
Subjects applied a nicotine patch (5 mg) in the morning and removed it at bedtime for one day.
Arm Title
Nicotine (10 mg)
Arm Type
Experimental
Arm Description
Subjects applied a nicotine patch (10 mg) in the morning and removed it at bedtime for one day.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Subjects applied a placebo patch (0 mg) in the morning and removed it at bedtime for one day.
Intervention Type
Drug
Intervention Name(s)
Nicotine (5 mg)
Intervention Description
Subjects applied a nicotine patch (5 mg) in the morning and removed it at bedtime for one day.
Intervention Type
Drug
Intervention Name(s)
Nicotine (10 mg)
Intervention Description
Subjects applied a nicotine patch (10 mg) in the morning and removed it at bedtime for one day.
Primary Outcome Measure Information:
Title
Pain Score
Description
Pain assessment by patient reported in visual analog score (VAS) with 0=no pain and 10=worst pain.
Time Frame
1 day
Secondary Outcome Measure Information:
Title
Patient Self-assessment of Psychological Distress
Description
Patient self-assessment of psychological distress in brief rating scale with no psychological distress=0 and maximum psychological distress=90.
Time Frame
1 day
Title
Number of Participants Who Reported an Increase in Daily Pain Medication Regime
Description
Number of participants who reported increases in daily pain medication after treatment with each intervention compared to their normal daily pain medication regime.
Time Frame
1 day
Title
Nausea
Description
Nausea assessment by patient reported on a numerical rating scale (NRS) with 0=no nausea and 10=extreme nausea.
Time Frame
1 day
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Chronic pelvic pain
Aged 18-60 years
Female
Exclusion Criteria:
Uncontrolled hypertension
Cardiovascular disease
Current analgesic abuse
Pregnancy
Current usage of nicotine patch or gum
Allergy to adhesive tape
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pamela Flood, MD
Organizational Affiliation
Columbia University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jessamyn Conell-Price, BA
Organizational Affiliation
Columbia University
Official's Role
Study Director
Facility Information:
Facility Name
Columbia University Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Effect of Nicotine on Chronic Pelvic Pain
We'll reach out to this number within 24 hrs